The Biology of ADHD — a Series

Neurodivergence
Series
Pathophysiology
ADHD is not one thing. Four independent strands of biology — prefrontal energy, immune-driven neuroinflammation, a dopamine-Nrf2-NLRP3 axis, and acquired trajectories — can each contribute to the symptom burden, and the way forward may be treating several of them at once. This is the landing page for a series that examines each strand and the multi-pathway treatment hypothesis.
Author

Yannick Loth

Published

August 24, 2026

ADHD is not one thing.

A common assumption is that the condition has a single cause and a single story. Our research points to something more granular: four distinct biological strands can underlie ADHD-related symptoms — a prefrontal energy deficit, an immune-driven neuroinflammatory subset, a dopamine-Nrf2-NLRP3 axis, and acquired features that are not developmental. Different patients likely carry different combinations of these, and each contributes a different slice of the daily symptom burden.

This series examines each strand in plain language, then asks the question they all converge on: can several pathways be treated at once to remove or dampen symptoms and give the patient a more normal life?


1 What we know, what our research adds

Every article in this series distinguishes two things clearly:

  1. What we know — established scientific findings, cited to the peer-reviewed literature. This includes ADHD’s own well-established science — its core dopamine neurobiology (Volkow et al. 2011), its genetic architecture and overlap with autism Lai et al. (2019), and its standard treatments — alongside the cross-disease findings (the prefrontal hypometabolism in ADHD (Zametkin et al. 1990), the inverted-U catecholamine pharmacology (Arnsten 2011), and the debated adult-onset trajectory Asherson and Agnew-Blais (2019)).
  2. What our research adds — the hypotheses our documentation project developed by reading across disease boundaries, and which are not yet established: the prefrontal-energy convergence model, the multi-pathway treatment hypothesis, the acquired-reversible framing, and the dopamine-Nrf2-NLRP3 cross-disease axis.

The distinction matters because the two are not the same confidence. “What we know” is evidence; “what our research adds” is testable hypothesis. The series keeps them separate so you are never misled into treating a hypothesis as a finding.

Each article follows the same shape:

  1. What it is — the mechanism, in ordinary words.
  2. The evidence — what supports it, and how strong that evidence is.
  3. The honest limits — what it does not claim.
  4. The decisive experiment — how the idea could be confirmed or refuted.

2 Part 1: ADHD as a Prefrontal Energy Disorder — and the Multi-Pathway Treatment Hypothesis

The series opens with the most developed strand: a prefrontal cortex running on a thin fuel supply. The prefrontal cortex is the most energy-expensive region in the human brain, so it is the first to degrade under any energy scarcity. Five independent lines — blood-flow failure, glucose hypometabolism, creatine depletion, catecholamine deficit, and an epidemiological gradient — converge on this single point. Part 1 also carries the series’ synthesis: the multi-pathway treatment hypothesis, and what treating several mechanisms at once could mean.

Read the article:

  1. ADHD as a Prefrontal Energy Disorder: Five Lines of Evidence, One Mechanism — what ADHD is on its own, the cerebrovascular, glucose, creatine, and catecholamine evidence, the epidemiological gradient, the honest limits, the decisive experiment, the slow-but-accurate open question, and the multi-pathway treatment hypothesis.

3 Part 2: The Immune and Neuroinflammatory Strand of ADHD

Not all ADHD may have the same cause. A growing line of evidence links ADHD-like features to chronic neuroinflammation and microglial activation — an immune-driven process that can deplete dopamine and degrade the same prefrontal circuits that primary ADHD affects through development. If some ADHD-like symptoms are driven by inflammation, they may be acquired, reversible, and identifiable.

Read the article:

  1. The Immune and Neuroinflammatory Strand of ADHD: When Inflammation Shapes Attention — the microglial evidence, the dopaminergic depletion route, the shared pro-inflammatory signal, the orexin-dopamine bridge, the kynurenine-dopamine bridge, the same-root hypothesis, and the honest limits.

4 Part 3: The Dopamine-Nrf2-NLRP3 Axis

A third strand links dopamine biology to the cell’s antioxidant-defense system and to the immune system’s central inflammatory switch. Low dopamine tone impairs Nrf2-driven antioxidant defenses, which in turn removes a brake on NLRP3-inflammasome activation — and the resulting inflammation further depletes dopamine, closing a self-amplifying loop. This cross-disease axis may explain why people with ADHD carry a lower threshold for post-infectious fatigue.

Read the article:

  1. The Dopamine-Nrf2-NLRP3 Axis: An Inflammatory Loop Behind ADHD and Fatigue — the dopamine-Nrf2 link, the Nrf2-NLRP3 brake, the feedback to dopamine synthesis, the BH4 bottleneck, ADHD’s own genetic architecture and its overlap with autism, the shared mitochondrial-genetic strand (haplogroup U, cybrid evidence), and the testable predictions.

5 Part 4: Acquired vs. Developmental — When ADHD-Like Features Might Be Reversible

The clinically consequential question: are ADHD-like features necessarily present from development, or can some be acquired — and therefore reversible? Much adult ADHD is not a straightforward continuation of childhood ADHD — some is adolescent-onset, some reflects missed or misrecalled childhood symptoms, some is explained by substance use or comorbidity — and acquired inattention after an immune trigger can be reversible when its cause is treated. Telling the two apart determines whether a symptom might respond to treating its cause or is stable wiring.

Read the article:

  1. Acquired vs. Developmental: When ADHD-Like Features Might Be Reversible — the adult-onset trajectory, the Architecture A/B/C framings, the interoceptive and neuroinflammatory routes, and the clinical consequences of getting the distinction wrong.

6 A note on honesty

Every article in this series distinguishes carefully what is confirmed by evidence, what is a promising hypothesis, and what is an individual patient’s experience. Most of the content here is at the hypothesis end — the certainties are explicit, often low, and nothing is presented as established clinical fact or a treatment recommendation.

The underlying science is drawn from our documentation project, which develops these cross-disease energy and immune models in detail. The ADHD-specific framing is our reading of the literature, written to stand alone for anyone curious about the biology.

Discuss any medical decision with a qualified clinician.

References

Arnsten, Amy F T. 2011. “Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks.” Biological Psychiatry 69 (12): e89–99. https://doi.org/10.1016/j.biopsych.2011.01.027.
Asherson, Philip, and Jessica Agnew-Blais. 2019. “Annual Research Review: Does Late-Onset Attention-Deficit/Hyperactivity Disorder Exist?” Journal of Child Psychology and Psychiatry 60 (4): 333–52. https://doi.org/10.1111/jcpp.13020.
Demontis, D., G. B. Walters, G. Athanasiadis, R. Walters, K. Therrien, T. T. Nielsen, L. Farajzadeh, et al. 2023. “Genome-Wide Analyses of ADHD Identify 27 Risk Loci, Refine the Genetic Architecture and Implicate Several Cognitive Domains.” Nature Genetics 55 (2): 198–208. https://doi.org/10.1038/s41588-022-01285-8.
Lai, Meng-Chuan, Caroline Kassee, J. Besney, S. Bonato, L. Hull, W. Mandy, P. Szatmari, and S. H. Ameis. 2019. “Prevalence of Co-Occurring Mental Health Diagnoses in the Autism Population: A Systematic Review and Meta-Analysis.” The Lancet Psychiatry 6 (10): 819–29. https://doi.org/10.1016/S2215-0366(19)30289-5.
Moffitt, Terrie E, Renate Houts, Philip Asherson, Daniel W Belsky, David L Corcoran, et al. 2015. “Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence from a Four-Decade Longitudinal Cohort Study.” American Journal of Psychiatry 172 (10): 967–77. https://doi.org/10.1176/appi.ajp.2015.14101266.
Sibley, Margaret H, Luis Augusto Rohde, James M Swanson, Lily T Hechtman, Brooke S G Molina, John T Mitchell, L Eugene Arnold, et al. 2018. “Late-Onset ADHD Reconsidered with Comprehensive Repeated Assessments Between Ages 10 and 25.” American Journal of Psychiatry 175 (2): 140–49. https://doi.org/10.1176/appi.ajp.2017.17030298.
Volkow, Nora D, Gene-Jack Wang, Jeffrey H Newcorn, Scott H Kollins, Timothy L Wigal, Frank Telang, Joanna S Fowler, et al. 2011. “Motivation Deficit in ADHD Is Associated with Dysfunction of the Dopamine Reward Pathway.” Molecular Psychiatry 16 (11): 1147–54. https://doi.org/10.1038/mp.2010.97.
Zametkin, Alan J, Thomas E Nordahl, Martin Gross, A Christina King, William E Semple, Judith Rumsey, Susan Hamburger, and Robert M Cohen. 1990. “Cerebral Glucose Metabolism in Adults with Hyperactivity of Childhood Onset.” New England Journal of Medicine 323 (20): 1361–66. https://doi.org/10.1056/NEJM199011153232001.